Sereprid

Quick links to important sections

Sereprid

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sereprid

Property Description
Active ingredient Tiapride (INN)
Form Tablet, Solution for Injection
Pharmacological class Atypical Antipsychotic
Common use Managing agitation and motor disturbances
Origin Synthetic, Substituted Benzamide Derivative

What Type of Medicine is Sereprid?

Sereprid is a prescription-only psychotropic drug whose active component is Tiapride. It is primarily classified as an atypical antipsychotic agent, placing it among the modern second-generation neuroleptic compounds. The Anatomical Therapeutic Chemical (ATC) classification system groups Tiapride within the Antipsychotics under the specific subgroup for Benzamides. The medicine is intended for central nervous system stabilization. Sereprid is a brand name used primarily in European markets, defining its distinct commercial positioning.


Composition and Available Forms of Tiapride

The fundamental chemical identity of Sereprid is defined by its sole active substance, Tiapride, which is a synthetic compound derived from the substituted benzamide chemical family. Tiapride is typically present in the final drug product as its hydrochloride salt. The medication is a single active ingredient product, supplied in multiple preparations. These forms include tablets for oral administration and a sterile solution for injection (IM or IV), which allows for different methods of delivery depending on the required onset or patient needs.


What is the General Purpose of Sereprid?

The general purpose of Sereprid is to produce a calming and stabilizing effect on psychomotor functions. Tiapride functions as a selective dopamine receptor antagonist, where it primarily blocks the activity of D2 and D3 dopamine receptors. This selective blockade of specific signaling pathways gives Sereprid its anti-agitation effect, making it a resource for managing intense restlessness, uncontrolled motor activity, and severe behavioral instabilities. A typical neutral use scenario for the drug's general profile involves stabilizing a patient experiencing acute psychomotor agitation.

What side effects are possible with Sereprid?

Official Descriptions of Side Effects and Safety Characteristics

The safety profile of Tiapride (Sereprid) is officially documented by regulatory authorities, which classify adverse reactions based on the physiological systems affected and their reported frequency. The safety information is organized according to the standards established in official government-mandated labels.

Commonly Documented Adverse Reactions

Adverse reactions classified as common (affecting up to 1 in 10 patients) typically involve neurological and general systemic effects. These frequently include somnolence (drowsiness), dizziness, and generalized asthenia (weakness or fatigue). Within the neurological domain, extrapyramidal disorders are common, characterized by symptoms like tremor, rigidity, and slowed movements. Additionally, hyperprolactinemia (an increase in the hormone prolactin) is classified as common, which can lead to reproductive and breast-related changes.

Adverse effects considered uncommon (affecting up to 1 in 100 patients) often involve the gastrointestinal system, including nausea, vomiting, and constipation, along with hypotension (low blood pressure) and weight gain. The reproductive system may be affected, with official listings including amenorrhea, galactorrhea, and erectile or orgasmic dysfunction.

Serious and Infrequent Safety Concerns

Regulatory documents highlight certain serious adverse reactions whose frequency may be not known or rare. These include the risk of Neuroleptic Malignant Syndrome (NMS), a potentially fatal condition involving muscle rigidity, fever, and changes in mental status. The medicine is also associated with a potential for QT prolongation, a change in the heart's electrical activity that can lead to severe cardiac arrhythmias.

Safety Patterns and Population-Specific Considerations

The timing of certain reactions is officially noted in labeling. Acute dystonia may appear early in the course of treatment, while tardive dyskinesia is associated with prolonged treatment exposure. For older adults, particularly those being managed for agitation, there is an increased susceptibility to side effects. For patients with renal impairment, official documents note that exposure to Tiapride is increased, requiring careful monitoring. The medicine is formally contraindicated in individuals with prolactin-dependent tumours.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Sereprid (Tiapride) overdose highlights the potential for severe and life-threatening complications, requiring immediate medical intervention.


Documented Overdose Manifestations

Symptoms officially documented for an overdose primarily involve the central nervous system and include severe drowsiness (somnolence), reduced alertness, and agitation. Other known side effects of the medicine may be intensified.

Serious Outcomes and Emergency Action

The most serious documented risk is the potential for QT interval prolongation, an electrical abnormality of the heart, which can progress to fatal ventricular arrhythmias, such as torsades de pointes, ventricular tachycardia, ventricular fibrillation, cardiac arrest, and sudden death.

Immediate medical attention and emergency medical treatment must be sought for any suspected overdose. There is no specific antidote listed in the official prescribing information; therefore, management is limited to symptomatic and supportive treatment.


Population-Specific Considerations

Specific caution and monitoring are advised for certain groups. Patients with renal impairment face an increased risk due to potential drug accumulation. The elderly population is also noted to have increased vulnerability to severe adverse effects, particularly intensified sedation.

Therapeutic Uses of Sereprid

Stabilizing Acute Agitation and Behavioral Disturbances

Sereprid (Tiapride) is commonly used across domains where additional symptomatic support is needed for addressing acute psychomotor instability and distressing behavioral manifestations. This is applicable within clinical settings that involve acute or disruptive symptom patterns, such as episodes of intense excitement, sudden aggressiveness, or pervasive restlessness. The medication is also relevant for managing agitation and aggression in the elderly. The medicine helps support a sense of stability when symptoms are more noticeable, contributing to a stabilizing effect that supports easing the overall symptom load of these manifestations.


Managing Involuntary Motor Activity and Acute Symptoms

Sereprid is relevant for easing symptom clusters related to hyperkinetic movement disorders, and may assist in addressing uncontrolled motor activity associated with specific neurological conditions. This is useful in conditions presenting with recurrent or episodic manifestations like dyskinesia and choreatic movements, including those linked to Huntington's disease. Furthermore, Sereprid plays a role in managing symptoms that create noticeable physiological strain, often used during phases when symptoms become more noticeable due to temporary physiological imbalance, and may assist in addressing tremors and associated anxiety during the management of alcohol withdrawal syndrome.

Quick Fact: Supportive Management for Severe Behavioral Instability and Involuntary Motor Symptoms

Eligibility and Restrictions for Use

Who Can and Cannot Use Sereprid?

This section outlines the official population eligibility and non-eligibility rules for Sereprid (Tiapride) as defined in government regulatory documents.

Contraindications (Must Not Use)

Sereprid is contraindicated and must not be used by patients with a documented hypersensitivity to the active substance (Tiapride) or any excipients. Absolute exclusion also applies to patients with prolactin-dependent tumours (such as pituitary prolactinoma or breast cancer) and those diagnosed with phaeochromocytoma. Use is also strictly contraindicated in patients with severe renal impairment.


Age and Condition Restrictions

Age Eligibility is primarily established for adult patients. Use is not recommended in children and adolescents (under 18 years), as regulatory agencies state that safety and efficacy have not been thoroughly investigated. Elderly patients require caution due to an increased risk of sedation.

Conditional Use is required for patients with a history of epilepsy (requiring close monitoring) and those with risk factors for QT interval prolongation. The medicine is not recommended for use during pregnancy, and breastfeeding must be discontinued during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This medication has a significant potential for drug-drug interactions that may require dosage adjustments for other medicines. The primary basis for these interactions is its effect on certain Cytochrome P450 (CYP) enzymes in the liver, which are responsible for metabolizing numerous other compounds.

  • It acts as an inducer of both the CYP3A4 and CYP2B6 enzymes, meaning it can decrease the levels and effectiveness of other medicines metabolized by these pathways. Dosage increases for co-administered drugs that are substrates of these enzymes may be necessary.
  • Conversely, it acts as an inhibitor of the CYP2C19 enzyme, which can lead to increased levels and potential toxicity of medicines metabolized by this pathway. Dose reduction of these concomitant drugs may be required.

Clinically Significant Interactions

Interacting Product Category Effect and Recommendation
Hormonal Contraceptives Effectiveness may be reduced. Use additional or alternative non-hormonal birth control methods.
CNS Depressants & Alcohol Additive effects may occur, increasing the risk of somnolence, dizziness, and fatigue. Use with caution.
Phenytoin Requires a gradual dosage decrease (up to 50%) for phenytoin.
Phenobarbital, Clobazam Dosage reduction of these drugs is often necessary.
Lamotrigine, Carbamazepine Dosage increase of these drugs may be required.

It is contraindicated for use in patients with Familial Short QT syndrome.

Mechanism of Action

Selective Dopamine Receptor Blockade

Sereprid, known chemically as Tiapride, exerts its effect primarily as an antagonist (blocker) on specific dopamine receptor subtypes, namely D2 and D3, located on postsynaptic neurons within the central nervous system. This direct binding interaction prevents the natural neurotransmitter dopamine from activating these receptors, thereby limiting the associated cellular response. This molecular action serves to dampen the overall excitatory signaling mediated by these receptors.


Modulating Neural Circuitry and Physiological Response

The mechanism of action is characterized by preferential modulation within specific neural circuits, including the mesolimbic and nigrostriatal systems. By altering signal transduction in these regulatory pathways, the drug influences neural activity associated with motor control and impulse regulation. This adjustment of localized dopaminergic tone affects signal transmission patterns within the circuits, leading to a physiological modulation of the systems involved.

Dosage and Administration Information

How to Use Sereprid (Risperidone) — Administration Guidelines

This section outlines the administration instructions for Sereprid (Risperidone) concerning the correct use of the medication.


Dosage Forms and Administration Routes

Sereprid is available in multiple oral forms, including tablets, oral solution (1 mg/mL), and orally disintegrating tablets (ODT). It is also available as a long-acting intramuscular (IM) or subcutaneous (SubQ) injectable suspension, which must not be administered intravenously (IV).

Standard Dosing and Schedule

Treatment typically begins with a low initial dose (e.g., 2 mg/day for adults), followed by a slow, gradual increase (titration) to a target maintenance dose (e.g., 4 to 8 mg/day). Oral forms are generally taken once or twice daily. Long-acting injections are administered by a healthcare professional at fixed intervals, such as every two weeks (IM) or monthly (SubQ).

Administration Conditions and Adjustments

Condition Official Instruction
With or Without Food Oral forms may be taken with or without food.
Tablet Handling Tablets must be swallowed whole; do not crush or chew.
Oral Solution Can be mixed with water, coffee, orange juice, or low-fat milk; do not mix with tea or cola.
Missed Dose (Oral) Do not take a double dose. Skip the missed dose and resume the next scheduled dose.
Population Adjustment A lower starting dose (e.g., 0.5 mg twice daily) is required for elderly patients and individuals with severe hepatic or renal impairment.

Procedural Note for Long-Acting Injection

Following the first administration of certain long-acting intramuscular forms, the patient must continue taking an oral antipsychotic for three weeks to ensure therapeutic levels are reached during the initial release period.

Recent Clinical Evidence

Research evidence / Overview of studies for Sereprid

Evidence for Managing Acute Psychomotor Agitation and Aggressiveness

Research examined Sereprid in older adults for its use in trials assessing short-term or episodic symptom patterns when experiencing conditions associated with acute or disruptive episodes of agitation. The research primarily involves short-term, controlled studies where symptoms were measured using standardized clinical assessment tools. In these research contexts, findings describe patterns observed in the studies related to how agitation was measured when compared to a non-active treatment (placebo). In comparative trials, research explored changes measured during the study period against other agents examined in the same studies. The outcomes reported in this evidence are generally focused on a very short time interval, often between two to four weeks.

Evidence for Use in Alcohol Withdrawal Syndrome (AWS)

Research has explored Sereprid in the context of conditions involving periods of heightened symptoms, specifically during the acute phase of Alcohol Withdrawal Syndrome (AWS). Studies monitored outcomes related to systemic or functional imbalance, using scales to measure the intensity of withdrawal symptoms. Research also examined Sereprid in the context of supporting abstinence. Findings describe patterns observed in these studies regarding how symptom severity was measured during acute withdrawal. However, when evaluating the longer-term outcomes related to abstinence over several months, the evidence suggests that findings were mixed across various studies. The reliability of this long-term data can be complicated because some studies experienced high dropout rates.

Evidence for Managing Hyperkinetic Movement Disorders

Available research for this indication is often derived from small, controlled, crossover trials where Sereprid was observed in limited populations, predominantly patients with Huntington’s chorea. Findings indicate patterns related to measurements of involuntary motor activity during the defined study period. The evidence that contributes to understanding symptom patterns here is primarily based on modest sample sizes and focuses on initial symptomatic change.

Areas of Uncertainty and Remaining Research Gaps

For all indications, the available clinical evidence consistently reflects research focusing on short-term changes and acute episodes. The long-term effects are not fully established across the evidence base for acute agitation, alcohol abstinence maintenance, or movement disorders. Follow-up durations were typically limited in the most relevant controlled trials. Data for certain groups remain insufficient, specifically concerning the use of Sereprid in pediatric populations. Comparative evidence or dedicated studies for pregnant individuals or patients with certain severe co-morbid medical conditions are lacking.

Key Studies & References Tiapride for the treatment of alcohol withdrawal syndrome and maintenance of abstinence (Systematic Review and Meta-analysis)

Frequently Asked Questions (FAQ)

Common questions about Sereprid (FAQ)


Q: How long does it usually take to feel the effects of Sereprid after starting treatment?

A: According to official product information, the medicine is absorbed rapidly, with maximum concentration in the blood typically reached within one to two hours after taking an oral dose. However, the full clinical response may follow the process of gradual dosage adjustment (titration) recommended by the prescribing healthcare professional.


Q: How long does Sereprid stay in your system?

A: Regulatory documents report the elimination half-life—the time it takes for half of the drug to be removed from the body—to be approximately 3.5 hours; however, individual patient factors can affect this clearance time. Sereprid is mainly removed from the body unmetabolized, primarily through the urine.


Q: Is Sereprid for short-term or long-term use?

A: Official research evidence is consistently focused on investigating the drug's effects over short-term intervals and during acute episodes of symptoms. The regulatory information notes that the long-term effects are not fully established across the evidence base for all uses, such as acute agitation or support for abstinence from alcohol.


Q: Does Sereprid cause weight gain or changes in metabolism?

A: Yes, official safety documents list weight gain as an uncommon adverse reaction, meaning it may affect up to 1 in 100 patients. This is listed as part of the known side effect profile of the medication.


Q: Can Sereprid be taken at the same time as other psychotropic medications?

A: Regulatory warnings state that taking Sereprid alongside other medications that affect the central nervous system (CNS) can lead to additive effects. This may increase common side effects like somnolence (drowsiness), dizziness, and fatigue. Changes in dosage for co-administered drugs may be required due to potential interactions.


Q: Does Sereprid interact with medications for high blood pressure or heart conditions?

A: Yes, Sereprid can potentially interact with these medications. It has the potential to cause hypotension (low blood pressure) and may enhance the effects of other drugs that lower blood pressure. It is also associated with a potential for QT prolongation, which is a change in the heart's electrical activity that is typically monitored by a healthcare provider.


Q: Is Sereprid generally considered safe for use in older adults?

A: Use in elderly patients requires special caution according to regulatory guidance. Older adults may be more susceptible to side effects, including increased sedation. Official guidance indicates that a lower starting dose is generally utilized for this population due to increased susceptibility to side effects.


Q: Is there a risk of withdrawal symptoms if Sereprid is stopped abruptly?

A: Regulatory information for drugs in this class suggests that withdrawal effects can occur upon cessation. For example, if used during pregnancy, there is a potential for neonatal drug withdrawal syndrome in the newborn. Discontinuing the medication should be done as directed by your prescribing physician.


Q: Is Sereprid used for managing symptoms of alcohol withdrawal syndrome?

A: Official research has explored Sereprid's use in the acute phase of Alcohol Withdrawal Syndrome (AWS). Studies monitored outcomes related to the severity of withdrawal symptoms and its use in supporting patient abstinence, though long-term evidence is mixed.


Q: Is Sereprid an antidepressant?

A: No, Sereprid is not classified as an antidepressant. The medicine's active component, Tiapride, is officially categorized as an atypical antipsychotic agent and is grouped within the Antipsychotics pharmacological subgroup by health organizations.


Q: Will Sereprid interfere with my birth control?

A: Official drug interaction warnings state that the effectiveness of hormonal contraceptives may be reduced while taking Sereprid. Official guidance indicates that additional or alternative non-hormonal birth control methods may be considered during treatment to maintain contraceptive effectiveness.


Q: Is Sereprid considered a 'selective' medication compared to older drugs?

A: Yes, Sereprid is formally characterized by its action as a selective dopamine receptor antagonist. This means its mechanism of action is focused on specifically blocking the activity of the D2 and D3 dopamine receptor subtypes.


Q: Can Sereprid be used to treat symptoms of agitation or aggression?

A: Sereprid is clinically recognized for its anti-agitation effect, making it valuable for managing intense restlessness and episodes of acute psychomotor agitation. Regulatory evidence specifically supports its use in older adults who exhibit aggressive behavior.


Q: What conditions besides psychosis might Sereprid be prescribed for?

A: Official product information and research evidence cover several uses. These include managing acute psychomotor agitation, supportive use during the acute phase of Alcohol Withdrawal Syndrome (AWS), and managing symptoms of certain hyperkinetic movement disorders, such as Huntington’s chorea.


Q: Is Sereprid the same as Tiapridal or Sereprile?

A: Sereprid is a brand name for the active component Tiapride. In various global markets, the same active substance, Tiapride, is also sold under other brand names, such as Tiapridal or Sereprile.


Q: Are movement side effects, like tremors or restlessness, common with Sereprid?

A: Yes, adverse reactions categorized as extrapyramidal disorders are classified as common (affecting up to 1 in 10 patients) in official documents. These disorders include symptoms such as tremor and rigidity, which are covered under the official classification.


Q: Does Sereprid increase prolactin levels, and what are the signs of this?

A: The medicine commonly causes an increase in prolactin hormone levels, known as hyperprolactinemia. In women, signs may include the absence of periods (amenorrhea) or abnormal milk flow (galactorrhea). In men, it may be associated with erectile or orgasmic dysfunction.


Q: Does Sereprid interact with any common pain relievers?

A: Sereprid can increase the effect of any medication that depresses the central nervous system, which includes certain classes of pain relievers. This combination can increase the risk of side effects such as excessive somnolence, dizziness, and fatigue.


Q: Why do some people need to take multiple doses of Sereprid per day?

A: Oral forms of the medication are officially prescribed to be taken once or twice daily. The drug has a relatively short elimination half-life, meaning it is cleared from the body quickly. Taking multiple doses is one method utilized to help maintain consistent therapeutic levels of the drug in the bloodstream throughout the day.


Q: Does Sereprid affect driving or operating machinery?

A: Yes, official safety information indicates that common side effects, such as somnolence (drowsiness) and dizziness, mean that your ability to drive or operate dangerous machinery may be impaired during the course of treatment.


Q: Is there any evidence for Sereprid's use in conditions not listed as its primary use?

A: Official research evidence is primarily limited to its established uses in agitation, alcohol withdrawal, and specific movement disorders. Regulatory documents indicate there are still research gaps, and data is consistently focused on short-term changes, meaning evidence for other conditions is generally not fully established.


Q: Does Sereprid affect other neurotransmitters besides dopamine?

A: The regulatory documents characterize Sereprid's pharmacological properties primarily through its action as a selective dopamine receptor antagonist on the D2 and D3 subtypes. Official descriptions focus exclusively on this specific dopaminergic mechanism.


Q: Do you need regular blood tests while taking Sereprid?

A: Patients with existing liver or kidney problems must start with a lower dose because drug exposure is increased. Patients with severe renal impairment are strictly contraindicated. This level of caution implies that monitoring of organ function is important for at-risk individuals.


Q: Is there a link between Sereprid and body temperature regulation?

A: Yes, Sereprid is associated with a rare but serious adverse reaction called Neuroleptic Malignant Syndrome (NMS). This potentially fatal condition involves severe symptoms, including a high fever and changes in mental status.


Q: Can Sereprid cause a drop in blood pressure when standing up?

A: The medicine is associated with general hypotension (low blood pressure) as an uncommon adverse reaction.


Q: Is Sereprid a good option for treating involuntary muscle contractions?

A: Official research has observed Sereprid's effect in patients with certain hyperkinetic movement disorders, such as Huntington’s chorea. Findings from these studies indicate patterns related to the measurement of involuntary motor activity.

How should Sereprid be stored and disposed of?

How to Store and Dispose of Sereprid?

The storage and disposal of Sereprid (Tiapride) must follow specific regulatory guidelines to maintain product quality and ensure environmental safety.

Storage and Handling Requirements

Dosage Form Mandatory Storage Condition Specific Constraint
Tablets Store below 25 C in the original carton. Protect from light and moisture.
Injection Store in original packaging. Do not refrigerate or freeze.

All forms of the medicine must be stored out of the sight and reach of children.

Product Stability and Disposal

Sereprid Solution for Injection must be used immediately after opening the ampoule. Regarding disposal, it is required that you ask your pharmacist how to throw away unused or expired medicine. Regulatory instructions explicitly prohibit throwing away this medicine via wastewater or household waste, protecting the environment from contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sereprid found in:

A-Z Index: